2025-03-09 - Analysis Report
## Merck & Co Inc (MRK) Stock Review

**0. Executive Summary:**

Merck & Co Inc (MRK) is a leading pharmaceutical company.  This report analyzes MRK's performance against the S&P 500 (VOO), examining its financial data, technical indicators, and recent earnings.  Key findings include significant underperformance relative to the S&P 500, high RSI indicating potential overbought conditions, and mixed earnings performance.


**1. Performance Comparison with S&P 500 (VOO):**

Merck & Co Inc (MRK) is a leading global biopharmaceutical company.

* **Cumulative Return (MRK):** 55.31%
* **Cumulative Return (VOO):** 108.62%
* **Return Difference:** -53.3%
* **Relative Divergence:** 24.0% (This means MRK's underperformance is in the 24th percentile relative to its historical range of under/outperformance against VOO.)

The data shows that MRK significantly underperformed the S&P 500 over the analyzed period.


**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | -2.0% | 11.8% | -0.1 | 109.9 |
| 2016-2018  | 46.0% | 11.8% | 0.5 | 153.8 |
| 2017-2019  | 44.0% | 11.8% | 0.3 | 188.1 |
| 2018-2020  | 32.0% | 9.4% | 0.2 | 174.6 |
| 2019-2021  | 3.0% | 14.3% | 0.2 | 177.6 |
| 2020-2022  | 47.0% | 14.3% | 0.2 | 265.4 |
| 2021-2023  | 55.0% | 14.3% | 0.3 | 268.1 |
| 2022-2024  | 21.0% | 9.5% | 0.3 | 251.3 |
| 2023-2025  | -31.0% | 9.5% | 0.1 | 239.1 |

The Alpha values indicate periods of both outperformance (positive Alpha) and underperformance (negative Alpha) relative to the market. Beta consistently exceeds 1, suggesting higher volatility than the market.


**2. Recent Price Movement:**

* **Closing Price:** $94.65
* **Previous Close:** $94.00
* **Change:** $0.69 (0.73% increase)  This represents a minor positive change.
* **5-Day Moving Average:** $93.51
* **20-Day Moving Average:** $89.09
* **60-Day Moving Average:** $95.32

The price is slightly above the 5-day and 20-day moving averages, but below the 60-day moving average, suggesting a recent upward trend but potential for further consolidation or correction.


**3. Technical Indicators:**

* **RSI:** 84.40  (High RSI suggests the stock may be overbought.)
* **PPO:** 1.18 (Positive PPO indicates bullish momentum.)
* **Recent (20-day) Relative Divergence Change:** +8.3% (Short-term upward trend)

The high RSI suggests the stock price might be susceptible to a correction despite the positive PPO and recent relative divergence. The price increase of $0.69 does not signal a significant, sudden movement (not a sharp upturn or downturn).  The expected return of 23.1% over the long term (2+ years) compared to the S&P 500 is substantial, but requires careful consideration of the high RSI and potential for correction.



**4. Recent Earnings Analysis:**

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2024-11-06 | 1.25 | $16.66B       |
| 2024-08-05 | 2.15 | $16.11B       |
| 2024-05-03 | 1.88 | $15.78B       |
| 2023-11-03 | 1.87 | $15.96B       |
| 2024-11-06 | 1.87 | $15.96B       | *(Duplicate entry, possibly an error)*

Revenue shows relatively stable performance, but EPS is volatile.  The duplicated entry needs clarification.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue  | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $15.62B | 75.50%       |
| 2024-09-30 | $16.66B | 75.51%       |
| 2024-06-30 | $16.11B | 76.76%       |
| 2024-03-31 | $15.78B | 77.56%       |
| 2023-12-31 | $14.63B | 73.26%       |

Revenue shows some fluctuation, but profit margins remain consistently high.

**Capital and Profitability:**

| Quarter | Equity   | ROE    |
|---------|----------|--------|
| 2024-12-31 | $46.31B | 8.08%  |
| 2024-09-30 | $44.50B | 7.09%  |
| 2024-06-30 | $43.58B | 12.52% |
| 2024-03-31 | $40.36B | 11.80% |
| 2023-12-31 | $37.58B | -3.26% |

Equity is growing, but ROE is volatile, showing a significant negative value in 2023-12-31.


**6. Overall Analysis:**

MRK's underperformance relative to the S&P 500 is significant. While the company demonstrates strong profit margins and generally stable revenue, the volatility in EPS and ROE, combined with a high RSI, suggests caution.  The predicted long-term outperformance should be considered in the context of these risks and the possibility of a price correction.  Further investigation is needed to understand the reasons behind the fluctuating earnings and to resolve the duplicated data entry in the recent earnings analysis.  The high beta indicates significant volatility, increasing the risk for investors.  A long-term investment strategy might be appropriate, but with awareness of potential short-term corrections.
